IL33 and leukemia: Thus, the data indicate that the efficacy of exogenous IL-33 administration appears to depend in part on tumor immunogenicity, which was also supported by the fact that IL-33 treatment did not directly affect leukemia cell viability in vitro (Figure 1D).